211: Biotech's catch-22, a $100 genome, & dealing with monkeypox
Will gene therapy ever live up to expectations? C…
June 2, 202233m 25s
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly? And is innovation actually bad for biotech? This week, health care strategist Jared Holz of Oppenheimer joins us to discuss the weekend's big oncology conference and what it will take to change Wall Street's dire view of the drug industry. We also discuss a weighty FDA meeting on gene therapy, the potential of a $100 genome, and how the expanding monkeypox outbreak is creating challenges for public health agencies.